BackMaze Therapeutics Overview
Maze Therapeutics, Inc.

Maze Therapeutics Target Price

See Maze Therapeutics's analyst price targets ($75) vs the current share price.

Get informed when a big investor buys or sells

+ Follow

Share Price

$31.07

Average Target Price

$75.00141.4% upside

1 analysts in the last 4 months

High: $75 | Low: $75

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-10-19Canaccord Genuity$75141.4% upsideOpen
2026-04-14Truist Financial$64106% upsideOpen
2026-03-17Truist FinancialDanielle Brill$68118.9% upsideOpen
2026-03-10Mizuho Securities$97212.2% upsideOpen
2026-01-19BTIG$4648.1% upsideOpen
2025-12-19GuggenheimDebjit Chattopadhyay$4648.1% upsideOpen
2025-12-04Wells Fargo$5577% upsideOpen
2025-12-03H.C. Wainwright$6093.1% upsideOpen
2025-11-13Raymond James$4854.5% upsideOpen
2025-09-15GuggenheimDebjit Chattopadhyay$349.4% upsideOpen
2025-09-02BTIG$303.4% downsideOpen
2025-07-08WedbushLaura Chico$1745.3% downsideOpen

Maze Therapeutics (MAZE) FAQ

Maze Therapeutics's target price stands at $75. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

The Street's average target of $75 for MAZE implies 141.4% upside versus today's price ($31.07). Positive implied upside usually reflects optimism on growth or margins, while a large downside can signal valuation or fundamental concerns. Check recommendation mix and recent target changes for more context.

The history chart shows how Maze Therapeutics's target price evolved across reporting periods, while the comparison chart places MAZE next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, target price is commonly used to spot outliers. Maze Therapeutics's reading of $75 is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.